Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 304-309

  Oshita, F ^a   Noda, K ^a   Nishiwaki, Y ^a   Fujita, A ^a   Kurita, Y ^a   Nakabayashi, T ^a   Tobise, K ^a   Abe, S ^a   Suzuki, S ^a   Hayashi, I ^a   Kawakami, Y ^a   Matsuda, T ^a   Tsuchiya, S ^a   Takahashi, S ^a   Tamura, T ^a   Saijo, N ^a  

^a NATIONAL CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ETOPOSIDE; GRANISETRON; IRINOTECAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; VOMITING;

EID: 0031015192     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.304     Document Type: Article

References (22)

1. Cozzarelli NR, Wang JC (eds): DNA Topology and Its Biological Effects. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1990
2. Wang JC: DNA topoisomerases: Why so many? J Biol Cheni 266:6659-6662, 1991
3. Osheroff N, Zechiedrich EL, Gale KC: Catalytic function of topoisomerase II. Bioassays 13:269-275, 1991
4. Liu LF: DNA topoisomerase poisons as anti-tumor drugs. Ann Rev Biochem 58:51-375, 1989
5. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16-20, 1992
6. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
7. Fukuda M, Nishio K, Kanzawa F, et al: Synergism between cisplatin and topoisomerase I inhibitors, NB506 and SN-38 in human small cell lung cancer cells. Cancer Res 56:789-793, 1996
8. Kanzawa F, Sugimoto Y, Minato K, et al: Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non- small cell lung cancer: Characterization and mechanism of resistance. Cancer Res 50:5919-5924, 1990
9. Karato A, Sasaki Y, Shinkai T, et al: Phase I study of CPT-11 and etoposide in patients with refractory solid tumor. J Clin Oncol 11:2030-2035, 1993
10. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication no. 48. Geneva, Switzerland, World Health Organization, 1979
11. Tobinai K, Kohno A, Shimada Y, et al: Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol 23:250-257, 1993
12. Abigerges D, Armand J-P, Chabot GG, et al: Irinotecan (CPT-11) high-dose escalation using intensive high-dose lo-peramide to control diarrhea. J Natl Cancer Inst 86:446-449, 1994
13. Gandia D, Abigerges D, Armand J-P, et al: CPT-11 induced cholinergic effects in cancer patients. J Clin Oncol 11:196-197, 1993 (letter)
14. Takasuna K, Kasai Y, Kitano Y, et al: Protective effects of Kampo medicine and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn J Cancer Res 86:978-984, 1995
15. Taguchi T, Wakui A, Hasegawa K, et al: Phase I clinical study of CPT-11. Gan To Kagaku Rhyho 17:115-120, 1990
16. Ferguson PJ, Fisher MH, Stephenson J, et al: Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res 48:5956-5964, 1988
17. Matsuo K, Kohno K, Tanano H, et al: Reduction of drug accumulation and DNA topoisomerase II activity in aquired teniposide-resistant human cancer KB cell lines. Cancer Res 50:5819-5824, 1990
18. Tsuruo T, Matsuzaki T, Matsushita M, et al: Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 21:71-74, 1988
19. Kaufman SH: Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51:1129-1136, 1991
20. Bertrand R, O'Connor MP, Kerrigan D, et al: Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 28A:743-748, 1992
21. Kim R, Hirabayashi N, Nishiyama M, et al: Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 50:760-766, 1992
22. Masuda N, Fukuoka M, Kudoh S, et al: Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 12:1833-1841, 1994